From the Guidelines
Ryaltris is a recommended treatment option for seasonal allergic rhinitis in adults and children 12 years and older, due to its combination of an antihistamine and a corticosteroid, which provides fast and long-lasting symptom relief. The medication contains olopatadine hydrochloride and mometasone furoate, with a standard dosage of two sprays in each nostril once daily 1. Olopatadine works quickly to block histamine receptors, providing fast relief from allergy symptoms like sneezing, itching, and runny nose, while mometasone reduces inflammation in the nasal passages for longer-lasting symptom control.
Key Considerations
- When using Ryaltris, prime the bottle before first use by pumping 6 times until a fine mist appears, and clean the nozzle regularly to prevent clogging.
- Common side effects may include altered taste, nosebleeds, and headache.
- Patients should use Ryaltris consistently during allergy season for optimal effectiveness, even when symptoms temporarily improve.
- If symptoms persist after 7 days of regular use, consult your healthcare provider as dosage adjustments or alternative treatments may be needed.
Evidence-Based Recommendation
The recommendation for Ryaltris is based on the evidence that intranasal corticosteroids, such as mometasone furoate, are the most effective medication class in controlling symptoms of allergic rhinitis 1. The combination of an antihistamine and a corticosteroid in Ryaltris provides a comprehensive treatment approach for seasonal allergic rhinitis. While intranasal corticosteroids may have local side effects, such as nasal irritation and bleeding, these are rare and can be avoided with proper administration technique 1.
Clinical Implications
In clinical practice, Ryaltris can be used as a first-line treatment option for seasonal allergic rhinitis, especially in patients who require rapid relief from symptoms. The medication's combination of an antihistamine and a corticosteroid makes it an effective treatment option for patients with moderate to severe symptoms. However, patients should be monitored for potential side effects and adjusted as needed to ensure optimal treatment outcomes.
From the Research
Ryaltris Overview
- Ryaltris is a combination intranasal corticosteroid and antihistamine spray used for the treatment of allergic rhinitis (AR) 2.
- It is a registered treatment option in Australia, along with Azelastine Hydrochloride and Fluticasone Propionate nasal spray (Dymista) 2.
Efficacy and Safety
- A study comparing Ryaltris (Olopatadine Hydrochloride and Mometasone Furoate Monohydrate) with Dymista (Azelastine Hydrochloride and Fluticasone Propionate) found that participants using Ryaltris had significantly higher total satisfaction index (TSI) scores than those using Dymista 2.
- The study also found that participants using Ryaltris were more satisfied with their overall treatment, particularly with sensory attributes, compared to those using Dymista 2.
- Another study compared the effects of Azelastine and Fluticasone nasal sprays in the treatment of allergic rhinitis and found that they had comparable efficacy in symptom control 3.
- A systematic review and meta-analysis found that combination therapy with intranasal azelastine and fluticasone propionate was superior to monotherapy in reducing patient-reported symptom scores in patients with allergic rhinitis 4.
Comparison with Other Treatments
- A comparative study found that fluticasone furoate produced sustained relief of symptoms, signs, and sensory attributes with a greater reduction in eosinophil count compared to azelastine hydrochloride in patients with allergic rhinitis 5.
- A randomized controlled trial found that a generic azelastine hydrochloride and fluticasone propionate nasal spray (AzeFlu) had equivalent effects to the original drug (MP-AzeFlu) in relieving symptoms and improving quality of life in patients with allergic rhinitis 6.
Patient Satisfaction
- A study found that participants using Ryaltris regarded 8 of 11 domains as significantly more important compared to participants using Dymista, with preferred domains being predominantly sensory attributes 2.
- The study suggests that prescribers of AR treatments should discuss treatment attributes with patients to facilitate shared decision-making 2.